[Strategies for the immunosuppressive therapy of intraocular inflammation].
Over the past two decades, therapeutic options for the treatment of intraocular inflammation (uveitis) have developed into a highly differentiated approach with an increasing number of drug options. In contrast to some other common sight-threatening ocular diseases, the majority of patients with uveitis can expect to receive treatment which will positively alter the course of their eye disease. Besides corticosteroids (CS) as primary systemic treatment, the most popular CS-sparing drug appears to be MTX in the treatment of uveitis. This paper suggests a strategy for the therapeutic approach to treating patients with intraocular inflammation. A table summarizes detailed information about mechanisms of action, dosage, and side effects, etc.
Becker
M D
MD
Interdisziplinäres Uveitiszentrum, Universität, Heidelberg. Matthias.Becker@uveitiszentrum.de
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D001682:Biological Availability; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D008657:Metabolic Clearance Rate; D012008:Recurrence; D014605:Uveitis / Q000188:drug therapy* / Q000276:immunology
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents